Evaluation of staging, cytoreduction and second-look operation of 119 ovarian cancer patients

Authors

  • Eddie Fernando Candido Murta Universidade de São Paulo
  • Jurandyr Moreira de Andrade Universidade de São Paulo
  • Maurício Mesquita Sabino de Freitas Universidade de São Paulo
  • Sérgio Bighetti Universidade de São Paulo

Keywords:

Ovarian cancer, Cytoreduction, Second look, Survival

Abstract

OBJECTIVE:This study was conducted on patients with ovarian cancer in order to evaluate survival. DESIGN: A retrospective study of 119 cases of ovarian cancer from January 1977 to December 1992 with observation until 1993. LOCATION: Department of Gynecology and Obstetrics, Ribeirão Preto School of Medicine, São Paulo University. PARTICIPANTS: Of the 119 cases, 70 (58.8%) presented epithelial carcinomas and 21 (17.6%) tumors of the sexual girdle/stroma. DATA SOURCE: The data were obtained from the medical records of the patients. MEASUREMENT: Statistical analysis of survival time was based on the nonparametric Mann-Whitney test with the level of significance set at P < 0.05. RESULTS: The patients with a negative second look had a mean survival of 79.4 ± 48.5 months versus 24.2 ± 15.1 months for patients with a positive second look (P < 0.02). CONCLUSIONS: It is concluded that patients with a negative second look present a better prognosis compared to those with residual disease.

Downloads

Download data is not yet available.

Author Biographies

Eddie Fernando Candido Murta, Universidade de São Paulo

Universidade de São Paulo, Ribeirão Preto School of Medicine, Hospital das Clínicas, Ribeirão Preto, São Paulo, Brazil.

Jurandyr Moreira de Andrade, Universidade de São Paulo

Universidade de São Paulo, Ribeirão Preto School of Medicine, Hospital das Clínicas, Ribeirão Preto, São Paulo, Brazil.

Maurício Mesquita Sabino de Freitas, Universidade de São Paulo

Universidade de São Paulo, Ribeirão Preto School of Medicine, Hospital das Clínicas, Ribeirão Preto, São Paulo, Brazil.

Sérgio Bighetti , Universidade de São Paulo

Universidade de São Paulo, Ribeirão Preto School of Medicine, Hospital das Clínicas, Ribeirão Preto, São Paulo, Brazil.

References

Feldman GB & Knapp RC. Lymphatic drainage of the peritonal cavity and its significance in ovarian cancer. Am J Obstet Gynecol 1974;119:991-4.

Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecoly 1978;52:100-4.

Rubin SC. Surgery for ovarian cancer. Hematol/Oncol Clin North Amer 1992;6:851-65.

Deutsch M, Beck D, Manor D, Brandes J. Metastatic brain tumor following negative second-look operation for ovarian carcinoma. Gynecol Oncol 1987;27:116-9.

LeRoux PD, Berger MS, Elliott JP, Tamimi- HK. Cerebral metastases from ovarian carcinoma. Cancer 1991;67:2194-9.

Hacker NF, Berek JS, Lagasse LD et al. Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 1983;61:413-20.

Dauplat J, Ferriere JP, Gorbinet M et al. Second-look laparotomy in managing epithelial ovarian carcinoma. Cancer 1986;57:1627-31.

Hoskins WJ, Rubin SC, Dulaney E et al. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian cancinoma. Gynecol Oncol 1989;34:365-9.

Lynch HT, Bewtra C, Lynch JF. Familial ovarian carcinoma. Clinical nuances. Am J Med 1986;81:1073-6.

Lund B, Jacobsen K, Rasch L et al. Correlation of abdominal ultrasound and computed tomography scans with second-or third-look laparotomy in patients with ovarian carcinoma. Gynecol Oncol 1990;37:279-83.

Murolo C, Costantini S, Foglia G et al. Ultrasound examination in ovarian cancer patients. A comparison with second look laparotomy. J Ultrasound Med 1989;8:441-5.

Berek JS, Knapp RC, Malkasian CD et al. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol 1986;67:685-9.

Niloff JM, Bast RJ, Schartzl EM, Knapp RC. Predective value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol 1985;151:981-6.

Munnell E. The changing prognosis and treatment in cancer of the ovary. Am J Obstet Gynecol 1968;100:790-805.

Conte P, Sertoli M, Bruzzone M et al. Cisplatin, methotrexate and 5-flourouracil combination chemotherapy for advanced ovarian cancer. Gynecol Oncol 1985;20:290-4.

Delgado G, Oram DH, Petrilli ES. Stage III epithelial ovarian cancer: The role of maximal surgical reduction. Gynecol Oncol 1984;18:293-7.

Louie K, Ozols R, Myers E et al. Long term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 1986;4:1579-82.

Sutton GP, Stehman FB, Einhorn LH et al. Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989;7:223-9.

Vogl S, Pagano M, Kaplan B et al. Cisplatin based combination chemotherapy for advanced ovarian cancer: High overall response rate with curative potential only in women with small tumor burdens. Cancer 1983;51:2024-30.

Dembo A. Radiotherapeutic management of ovarian cancer. Semin Oncol 1984;11:238-41.

Fuks Z, Rizel S, Anteby S et al. The multinodal approach to the treatment of Stage IV ovarian carcinoma. Int J Radiat Oncol Biol Phys 1982;8:903-7.

Downloads

Published

1997-09-09

How to Cite

1.
Murta EFC, Andrade JM de, Freitas MMS de, Bighetti S. Evaluation of staging, cytoreduction and second-look operation of 119 ovarian cancer patients. Sao Paulo Med J [Internet]. 1997 Sep. 9 [cited 2026 Aug. 11];115(5):1542-7. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/2147

Issue

Vol. 115 No. 5 (1997)

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.